119 related articles for article (PubMed ID: 26360548)
1. Efficacy of cytarabine, aclarubicin and granulocyte colony-stimulating factor (CAG) regimen compared to FLAG regimen for adult patients with relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Li X; Liu L; Zhang Y; Qu Q; Yao Y; Wang T; Jiao W; Wu D
Leuk Res; 2015 Aug; ():. PubMed ID: 26360548
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Liu L; Jiao W; Zhang Y; Qu Q; Li X; Wu D
Leuk Res; 2015 Mar; 39(3):323-8. PubMed ID: 25638269
[TBL] [Abstract][Full Text] [Related]
3. Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.
Liu L; Qu Q; Jiao W; Zhang Y; Li X; Ding C; Wu D
Leuk Res; 2015 Aug; 39(8):805-11. PubMed ID: 26021434
[TBL] [Abstract][Full Text] [Related]
4. Cladribine with Granulocyte Colony-Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study.
Wang H; Wang L; Li C; Wuxiao Z; Shao R; Wang H; Lu Y
Oncologist; 2020 Nov; 25(11):e1663-e1670. PubMed ID: 32845551
[TBL] [Abstract][Full Text] [Related]
5. Increasing aclarubicin dosage of the conventional CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen is more efficacious as a salvage therapy than CAG for relapsed/refractory acute myeloid leukemia.
Qu Q; Liu L; Zhang Y; Li X; Wu D
Leuk Res; 2015 Dec; 39(12):1353-9. PubMed ID: 26432074
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of high-dose cytarabine and aclarubicin in combination with G-CSF regimen compared to intermediate/high-dose cytarabine and standard-dose cytarabine induction regimen for non-remission acute myeloid leukemia.
Lei M; Liu L; Wang Z; Wu D
Indian J Cancer; 2019; 56(2):167-172. PubMed ID: 31062738
[TBL] [Abstract][Full Text] [Related]
7. Increasing the dose of aclarubicin in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) can safely and effectively treat relapsed or refractory acute myeloid leukemia.
Liu L; Zhang Y; Jin Z; Zhang X; Zhao G; Si Y; Lin G; Ma A; Sun Y; Wang L; Wu D
Int J Hematol; 2014; 99(5):603-8. PubMed ID: 24623261
[TBL] [Abstract][Full Text] [Related]
8. Low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: a retrospective study of 25 Chinese patients.
Xue SL; Cui HX; Zou JY; Xue MX; Tang XW; Zhang YM; Wu DP
Hematol Oncol; 2013 Dec; 31(4):206-12. PubMed ID: 23616245
[TBL] [Abstract][Full Text] [Related]
9. [The comparative study of the effects between modified FLAG and CAG on relapsed or refractory acute myeloid leukemia].
Wang T; Ma L; Zhu Q; Gong R; Gao Z; Tian W
Zhonghua Xue Ye Xue Za Zhi; 2014 Nov; 35(11):966-9. PubMed ID: 25417870
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
[TBL] [Abstract][Full Text] [Related]
11. Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy.
Zhu HH; Jiang H; Jiang B; Lu J; Jiang Q; Bao L; Zhang XH; Qin YZ; Huang XJ
Leuk Lymphoma; 2013 Nov; 54(11):2452-7. PubMed ID: 23432721
[TBL] [Abstract][Full Text] [Related]
12. CAG regimen for refractory or relapsed adult T-cell acute lymphoblastic leukemia: A retrospective, multicenter, cohort study.
Qian JJ; Hu X; Wang Y; Zhang Y; Du J; Yang M; Tong H; Qian WB; Wei J; Yu W; Lou YJ; Mao L; Tao Meng H; You LS; Wang L; Li X; Huang X; Cao LH; Zhao JZ; Yan Yan X; Chen YB; Chen Y; Zhang SJ; Jin J; Hu J; Zhu HH
Cancer Med; 2020 Aug; 9(15):5327-5334. PubMed ID: 32492289
[TBL] [Abstract][Full Text] [Related]
13. [Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in 50 patients with relapsed acute myeloid leukemia].
Zhu BG; Qian SX; Hong M; Lu H; Wu HX; Zhang SJ; Qiu HX; Xu W; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):760-4. PubMed ID: 19549403
[TBL] [Abstract][Full Text] [Related]
14. FLAG/FLAG-IDA regimen for children with relapsed/refractory acute leukemia in the era of targeted novel therapies.
Mustafa O; Abdalla K; AlAzmi AA; Elimam N; Abrar MB; Jastaniah W
J Oncol Pharm Pract; 2019 Dec; 25(8):1831-1838. PubMed ID: 30518307
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in MDS-EB and AML-MRC].
Liu J; Jia JS; Gong LZ; Lu SY; Zhu HH; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):734-738. PubMed ID: 30369183
[No Abstract] [Full Text] [Related]
16. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA].
Su JY; Chang CK; Zhang X; Zhou LY; Song LQ; Xu L; Wu LY; He Q; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):459-63. PubMed ID: 19379588
[TBL] [Abstract][Full Text] [Related]
18. The Efficacy of Fludarabine, High Dose Cytosine Arabinoside with Granulocyte Colony Stimulating Factor (FLAG) Protocol as Salvage Therapy for Refractory/Relapsed Acute Leukemias in Adult Iraqi Patients.
Alwan AF; Matti BF; Naji AS; Jawad AM
Indian J Hematol Blood Transfus; 2014 Dec; 30(4):231-5. PubMed ID: 25435719
[TBL] [Abstract][Full Text] [Related]
19. Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia.
Jin J; Chen J; Suo S; Qian W; Meng H; Mai W; Tong H; Huang J; Yu W; Wei J; Lou Y
Leuk Lymphoma; 2015 Jun; 56(6):1691-7. PubMed ID: 25257348
[TBL] [Abstract][Full Text] [Related]
20. CAG regimen enables relapsed or refractory T-cell acute lymphocytic leukemia patients to achieve complete remission: a report of six cases.
Xue SL; Wu DP; Sun AN; Tang XW
Am J Hematol; 2008 Feb; 83(2):167-70. PubMed ID: 17874449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
